Public Disclosure of FDA Panel Members' Conflicts of Interest | GenomeWeb

The Scientist reports that the FDA is changing its conflict-of-interest policy. In the past, if they wanted an interest waiver, the members of the organization's 32 advisory panels and committees would simply have to tell the FDA if they had any connections with a company that had a drug or medical device under FDA review, or with one of its competitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.